CLINICAL TRIAL: RITUXIMAB IN SUBJECTS WITH ISN/RPS CLASS III OR IV LUPUS NEPHRIT

临床试验：利妥昔单抗用于 ISN/RPS III 或 IV 级狼疮肾病受试者

• 批准号: 7717897
• 负责人: ELIZA F CHAKRAVARTY
• 金额: $ 0.05万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-12-01 至 2008-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7717897
• 关键词: B-Lymphocytes; Class; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Inflammation; Institution; Lupus; Lupus Nephritis; Monoclonal Antibodies; Numbers; Patients; Placebos; Proteins; Purpose; Research; Research Personnel; Resources; Safety; Signs and Symptoms; Source; United States National Institutes of Health; design; mycophenolate mofetil; rituximab

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to investigate the safety and efficacy of rituximab in combination with mycophenolate mofetil (MMF) compared with placebo in combination with MMF in the treatment of lupus nephritis. Rituximab is a monoclonal antibody, which is a protein that helps protect the body against foreign materials. It decreases some types of B-cells in the body which may be important in inflammation. Rituximab has been used in a small number of patient with lupus nephritis, and this study is designed to further evaluate whether rituximab would reduce the signs and symptoms of lupus and lupus nephritis.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这项研究的目的是研究利妥昔单抗与霉酚酸酯（MMF）结合安慰剂与MMF联合治疗狼疮肾炎的安全性和功效。 利妥昔单抗是一种单克隆抗体，是一种有助于保护人体免受异物的蛋白质。 它减少了体内某些类型的B细胞，这可能在炎症中很重要。 利妥昔单抗已用于少量狼疮肾炎患者，该研究旨在进一步评估利妥昔单抗是否会减少狼疮和狼疮肾炎的体征和症状。